Spiros P Hiotis, MD, PhD
img_Spiros P Hiotis
PROFESSOR | Surgery
PROFESSOR | Oncological Sciences
Are you a patient?
Specialties
Surgery, Surgical Oncology

Dr.  Hiotis is currently the Vice Chairman for Surgical Research at Mount Sinai. In this role, Dr. Hiotis administrates the coordinated clinical and basic science research efforts of a large department, including ten divisions and multiple full-time faculty members. He supervises the department’s research fellows, coordinators, and assistants.

In addition to his administrative responsibilities in research, Dr. Hiotis also maintains a research endeavor of his own, oversees a basic science laboratory, and is the principal investigator of independently-funded scientific research. He is also actively engaged in several clinical trials.

His recent open protocols include:

  • Hepatocellular carcinoma in non-cirrhotic hepatitis B patient; a prospective analysis of a fibrosis-independent pathway to cancer based on hepatitis B viral DNA levels.
  • Treatment of advanced metastatic hepatocellular carcinoma with autologous dendritic cell vaccination
  • Cell based immunotherapy of a model for hepatocellular carcinoma
  • Risk factors for peritoneal disease and recurrence in gastric cancer
  • Factors associated with improved survival in patients with gall bladder cancer

PhD, University of South Florida

Residency, Surgery (General Surgery), University of Southern Florida

Fellowship, Surgical Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Surgery

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Hiotis did not report having any of the following types of financial relationships with industry and other outside entities during 2023 and/or 2024: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.